Results 181 to 190 of about 163,674 (312)

A Retrospective Study of Adult and Pediatric D‐Dimer Tests to Identify Opportunities for Improved Utilization

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction D‐dimers are produced by lysis of cross‐linked fibrin. In children, D‐dimer testing is used to evaluate disseminated intravascular coagulation (DIC) and some inflammatory states, but its use is not validated for screening or ruling out suspected venous thromboembolic events (VTE).
Rabab Al Dawood   +4 more
wiley   +1 more source

Temporal trends in glycaemia and hospital outcomes in three metropolitan Australian hospitals, 2017–2024

open access: yesInternal Medicine Journal, EarlyView.
ABSTRACT Background Longitudinal data on in‐hospital glycaemia from Australian hospitals are limited. Aims: The aim of this study was to evaluate the efficacy and safety of current inpatient management strategies in New South Wales hospitals and to compare hospital‐acquired complication (HAC) rates in patients with and without diabetes.
Barbara Depczynski   +2 more
wiley   +1 more source

Leadless Versus Transvenous Dual‐Chamber Pacemakers: Real‐World Evidence From AVEIR DR Coverage With Evidence Development Study

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background AVEIR DR, an industry‐first dual‐chamber leadless pacemaker (LP), provides continuous atrioventricular synchrony through implant‐to‐implant (i2i) communication between atrial and ventricular LP devices. It is important to evaluate the early real‐world comparative safety of AVEIR DR LP.
Monica Lo   +10 more
wiley   +1 more source

Focus on ST elevation myocardial infarction [PDF]

open access: yesEuropean Heart Journal: Acute Cardiovascular Care, 2019
openaire   +2 more sources

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat   +22 more
wiley   +1 more source

Cardioprotective therapies for ST-elevation myocardial infarction: the emerging role of thyroid hormone: a narrative review. [PDF]

open access: yesFront Endocrinol (Lausanne)
Grigoriou K   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy